Immunoassay Markets (Infectious Disease, Tumor Markers, Thyroid, Allergy, Drugs of Abuse, Therapeutic Drug Monitoring, Others)
This report, from Kalorama Information, the premier market research publisher in in vitro diagnostics, features the following market data:
Global Immunoassay Market, 2017-2021
Historical Market 2014-2016
Lab-baded Immuonassay Markets
Infectious Disease Immunoassays – (Hepatitis, HIV, STD, TORCH, Respiratory, HAIs, Other Infectious Disease)
Tumor Marker Immunoassays
Metabolic and Other Hormone Immunoassays
Therapeutic Drug Monitoring Immunoassays
Drugs of Abuse Immunoassays
Transplant Medicine, IBD, Alzheimer’s and Other Areas of Disease Innovation
International and Emerging Markets
The immunoassay market is a large, well-established market with $ . billion in sales in . This market consists of three major segments: immunoassays performed in centralized laboratories for clinical indications such as screening, diagnosis, and/or monitoring patients, point-of-care or rapid immunoassays also performed for clinical indications, and immunoassays performed to screen the blood supply to prevent transfusion-transmitted infections.
Immunoassays are tests that are based on the binding of antibodies to antigens to identify the presence of a substance (an analyte). Immunoassays have been used in clinical laboratory medicine since the 1960s, and are indispensable tools in clinical diagnostics. A wide range of types of immunoassays is now used to measure proteins (including antibodies), hormones, drugs, and other analytes. Fully automated immunoassay systems are now found in clinical laboratories. Even though the field of immunoassays is now mature, companies have continued to develop new immunoassays and immunoassay instrument platforms to improve the sensitivity of the assays. New developments are designed to make multiplexing possible, to miniaturize the platforms for point-ofcare, and to identify and develop assays for novel biomarkers, thus further expanding the potential of immunoassays for the future.
Prospects for growth in the immunoassay market are good in certain geographical regions of the world (developing countries). Several factors are driving the growth of diagnostic testing, including testing with lateral flow devices, in these markets. One major factor is economics. There is a growing middle class population that is increasingly insured in many countries in South East Asia and Latin America, and these patients are better able to pay for services. In addition, increased availability of health insurance in emerging companies such as China and India is helping to fuel this growth. These and other factors will make these regions promising segments of the immunoassay market. The report provides more specific data regarding immunoassay growth.
The central lab-based immunoassays market is by far the largest segment of the total immunoassay market with 70.6% of this market in 2016. Centralized laboratories include reference laboratories (such as Laboratory Corporation of America or LabCorp, Quest Diagnostics, and others), hospital laboratories, laboratories operated by health maintenance organizations (HMOs), and other centralized laboratories. These laboratories range from very high volume labs down to smaller labs, but they typically use the fully automated immunoassay and chemistry/immunoassay analyzers discussed in the report for their high volume immunoassay tests. They may also have other platforms for tests that are not as high volume, and therefore are not on the fully automated platforms.
The market for point-of-care (POC) testing consists of two segments, self-testing (also referred to as the over-the-counter or OTC segment), and professional POC testing. However, there are many locations where POC testing can occur within these segments, especially the professional POC market. Professional POC testing is performed in a number of different settings including in hospitals, physicians office laboratories (POLs) and clinics, retail clinics, and many other locations.
Immunoassays also play a role in blood testing (or blood screening) market, which represents only 3.5% of the total immunoassay market. In developed countries, all units of blood and blood products are already screened for several infectious agents. Growth of the blood testing market in these countries is primarily driven by changes in the numbers of units donated and being screened. An exception and potentially significant step increase in the size of this market could occur if it is mandated that a new (additional) immunoassay be used to screen blood for an additional disease. In some developing countries, not all units of blood and blood products are screened for every recommended infectious agent. Additional growth could occur in these markets as more of the blood supply is screened. However, Kalorama expects that the overall, worldwide market for immunoassays used to screen blood will continue to grow slowly.
Market data in this report are based on factory sales to the end user, and not on retail pricing or reimbursement payments. The dollar value of a market segment is proportional to the number of tests performed, because the cost of the instrumentation is generally buried in the per test price.